Our Story

I am a research scientist with 18 years of experience in early-stage drug development. I have consistently integrated chemical, biological, and computational methodologies to advance novel therapeutics discovery and design. Along my journey, I have applied multistep organic synthesis, solid-phase peptide synthesis, and synthetic biology to produce potential candidates. I have mastered state-of-the-art analytical techniques in chromatography, mass spectrometry, and nuclear magnetic resonance to purify and fully characterise them. Finally, I have integrated advanced statistics, structural bioinformatics, and artificial intelligence (AI) to streamline R&D processes in natural product drug discovery and peptide drug design campaigns.

​​

I have contributed to five international research collaborations between academic institutions and industry partners, including Pierre Fabre Laboratories (FR), Noscira (ES), Prizer (US), and Protagonist Therapeutics (AUS). Through these partnerships, I gained extensive experience navigating IP-sensitive environments, working with multidisciplinary teams, and aligning academic research with industry needs. Our hybrid strategies were applied to biologically relevant protein drug targets (kinases, GPCRs, transcription factors) and phenotypic screenings in applications ranging from cancer treatments and type 2 diabetes, neurodegenerative disorders, neglected diseases (malaria, leishmania), and antibiotic resistance. I have also engaged with growers in the Americas to explore crop protection solutions.

​​​

Hit discovery and lead generation are often hindered by high attrition rates, limited chemical diversity, and the time-intensive nature of experimental validation. Traditional approaches rely on costly, trial-and-error processes that can delay the identification of viable candidates. By integrating data-driven strategies and AI, I am convinced we can analyse vast datasets, predict molecular properties, and optimise lead compounds more efficiently, reducing the time it takes to find the needle in the haystack.

​

To address these challenges, I founded Ingenie Bio to harness AI and computational technologies in biomolecular design. Our mission is to streamline discovery pipelines, reduce experimental inefficiencies, and increase success rates. By identifying biomolecules with desired properties and functions, we accelerate their transition from potential candidates to market-ready solutions, pushing the boundaries of AI and Life Sciences.

​

Fabien Plisson, PhD